Labetuzumab-PE40 conjugateAlternative Names: Anti-CEA monoclonal antibody MN14-PE40 conjugate; hMN14(sFv)-PE40 immunotoxin
Latest Information Update: 16 Aug 2002
At a glance
- Originator Immunomedics
- Class Antineoplastics; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 11 Dec 1998 New profile
- 11 Dec 1998 Preclinical development for Cancer in USA (Unknown route)